ImmunoPrecise Antibodies Ltd.
HYFTNASDAQHealthcare·US · USD
$1.50
+0.07 (+4.55%)
Prices as of October 9, 2026 · market closedPrice
Key statistics
Valuation
Market cap67.37M USD
Enterprise value48.48M USD
Trailing P/E-4.61
Forward P/E-5.64
PEG ratio0.00
Price / sales4.35
Price / book14.54
Profitability
Gross margin60.63%
Operating margin-159.86%
Profit margin-105.20%
Return on assets-36.39%
Return on equity-123.66%
Income (TTM)
Revenue11.42M USD
Gross profit6.94M USD
EBITDA-11.33M USD
Net income-12.03M USD
Diluted EPS-$0.26
Rev. growth (YoY)21.30%
Balance sheet
Total cash5.37M USD
Total debt2.45M USD
Debt / equity50.41
Current ratio1.84
Book value / share$0.10
Cash flow (TTM)
Operating cash flow-8.65M USD
Levered free cash flow6.18M USD
Shares & price
Shares outstanding46.71M
Float42.75M
Held by institutions9.29%
Beta0.78
50-day MA$1.35
200-day MA$1.47
52-week high$2.99
52-week low$0.99
Dividends
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-09-14-0.05-0.09−80.00%2026-07-22-0.05-0.06−20.00%2026-05-212.603.64+40.00%2026-05-074.194.70+12.17%2026-03-12-0.04-0.06−50.00%
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jennifer Lynne Bath Ph.D.
- Employees
- 74
- Headquarters
- Austin, TX, United States
- Website
- www.mindwalkai.com